Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.
New venture in oral health with Symrise and cooperation with Viva 5 boosts company's ability to grow in North America.
January 23, 2013
2 Min Read
Fourth quarter 2012:
Total operating revenue amounted to msek 26.3 (24.7).
Net sales amounted to msek 26.2 (24.6).
Operating profit totalled msek 2.6 (loss: 0.7).
Profit after tax amounted to msek 2.1 (loss: 0.3).
Profit after tax per share was sek 0.24 (loss: 0.03).
Cash flow amounted to msek 1.2 (neg: 0.7).
Full-year 2012:
Total operating revenue amounted to msek 100.4 (95.0).
Net sales amounted to msek 99.6 (94.4).
Operating profit totalled msek 17.2 (17.8).
Profit after tax amounted to msek 13.5 (14.2).
Profit after tax per share was sek 1.48 (1.54).
Cash flow amounted to msek 11.1 (neg: 13.6).
Significant events during the fourth quarter:
Probi signed a business development agreement with U.S.-based probiotic specialist Viva 5.
Probi and German company Symrise signed a research and development agreement pertaining to innovative probiotic products with documented health benefits.
The clinical studies conducted by Probi during the year in immune and gastrointestinal health were completed without achieving the anticipated results.
Probi’s environmental management system was certified according to ISO 14001.
The Board of Directors proposes a dividend totalling MSEK 6.8 (6.8), corresponding to SEK 0.75 (0.75) per share.
“Our total net sales for 2012 amounted to approximately MSEK 100, up 6 percent. Excluding ProViva, sales increased by 14 percent despite the prevailing economic climate. During the year, we signed a total of six new agreements. I would like to underscore the importance of the two agreements that were signed in December, the new venture in oral health with Symrise and the cooperation with Viva 5, which boosts our ability to grow in the important North American market. Our two major clinical studies in immune and gastrointestinal health that were completed in 2012 did not yield the anticipated results. However, our products—Probi Digestis® and Probi Defendum®—are based on strong data from a large number of previous clinical studies. Accordingly, they are still competitive on the international market and are purchased by consumers since their health is tangibly improved. We are now focusing on evaluating the studies and will launch new studies in 2013, which will form the basis for EFSA applications,” says Michael Oredsson, CEO of Probi.
You May Also Like
